Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.14) by 18.42 percent. This is a 133.82 percent decrease over earnings of $2.75 per share from the same period last year. The company reported quarterly sales of $73.737 million which missed the analyst consensus estimate of $79.991 million by 7.82 percent. This is a 86.41 percent decrease over sales of $542.709 million the same period last year.